Statin shows promise for COPD inflammation in small trial
NCT ID NCT07549932
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study tested whether adding a daily statin (atorvastatin 20 mg) to standard treatment for six months could reduce airway inflammation and improve lung function in 80 people with severe COPD. Researchers measured blood markers of inflammation and breathing tests. The goal was to see if this cheap, widely available drug could offer extra benefits for COPD management.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atorvastatin (statin)
- What this could lead to
- If statins prove helpful, they could become a low-cost add-on treatment to reduce inflammation and slow COPD progression.
- What could go wrong
- This is a small, completed study with no phase designation, so results may not be conclusive. Statins also carry risks like muscle pain or liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIRWAY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
utpatient clinic and Inpatient quarters of the Thoracic Medicine Department of Mansoura University Hospitals
Al Mansurah, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- Which inhaler breathes better? a Head-to-Head COPD showdown
- Could tiny lung valves revive heart and muscle strength in COPD?
- One lung or two? surgery trial aims to find the best approach for severe COPD